



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM)

Citation for published version:

Treat_CCM Investigators 2022, 'Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial', *Lancet Neurology*, vol. 22, no. 1, pp. 35-44. [https://doi.org/10.1016/S1474-4422\(22\)00409-4](https://doi.org/10.1016/S1474-4422(22)00409-4)

Digital Object Identifier (DOI):

[10.1016/S1474-4422\(22\)00409-4](https://doi.org/10.1016/S1474-4422(22)00409-4)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Lancet Neurology

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Figure 1 – Trial profile

*Included in propranolol per-protocol population



